Дифлазон (Fluconazole) is generally used across several major therapeutic domains to provide symptomatic antifungal support. The medication is generally considered relevant for addressing severe systemic infections, including those affecting the central nervous system and the management of systemic fungal issues.

It is applied across domains where additional symptomatic support is needed in situations involving: Systemic Fungal Diseases, such as Candidemia and disseminated candidiasis; Specific Central Nervous System Infections, notably Cryptococcal meningitis; Localized Mucosal Infections, including oral thrush and vaginal candidiasis; and Prophylaxis (prevention) in patients at high risk due to conditions like HIV/AIDS or treatments such as chemotherapy.

The therapeutic benefit generally provides support that helps ease the overall symptom burden associated with acute, systemic manifestations like persistent fevers, and may assist with supportive relief when localized symptoms like burning and pain create noticeable physiological strain.

“It plays a role in managing symptoms related to systemic imbalance and supports general well-being during symptomatic phases.”

Quick Fact: Relief for Symptomatic Discomfort
Дифлазон is commonly used to help with symptom clusters that may become intense or disruptive, especially those associated with localized inflammation and systemic fungal activity.

Who can and cannot use Дифлазон (Fluconazole)?

Official regulatory documents strictly define the population eligibility for Дифлазон (Fluconazole) based on patient status, comorbidities, and co-medications.

Absolute Contraindications

Fluconazole use is contraindicated in patients with a known hypersensitivity to Fluconazole, related azole substances, or any product excipients. Use is also strictly prohibited when the patient is simultaneously taking specific medicinal products that prolong the QT interval and are metabolized by the CYP3A4 enzyme, such as cisapride, terfenadine, or erythromycin. Co-administration under these conditions creates a risk of serious cardiac events.

---

Conditional Eligibility and Restrictions

• Organ Function: Use requires caution and monitoring in patients with pre-existing hepatic (liver) or renal (kidney) impairment. Dose adjustments are mandatory for multiple-dose regimens in cases of moderate to severe renal impairment.
• Reproductive Status: The medicine is generally not recommended during pregnancy or lactation. High-dose, long-term use during the first trimester of pregnancy is strongly restricted due to associated risks.
• Age Groups: The drug is approved for adults and the pediatric population for specific indications. Neonates (infants under four weeks old) require extended dosing intervals due to slower excretion. Safety and efficacy for certain pediatric indications, such as genital candidiasis, remain not established.

Interactions with other medicines and products

Fluconazole (Дифлазон) is a potent inhibitor of the cytochrome P450 enzymes CYP2C9 and CYP2C19, and a moderate inhibitor of CYP3A4. This enzyme inhibition reduces the clearance of numerous co-administered medicines, leading to increased plasma concentrations and a higher risk of adverse effects. The inhibitory effect may persist for four to five days after treatment discontinuation.

Contraindicated Combinations

Concomitant use is strictly contraindicated with drugs known to prolong the QT interval that are metabolized by CYP3A4. These include: Astemizole, Cisapride, Erythromycin, Pimozide, and Quinidine. Co-administration with Terfenadine is also contraindicated when Fluconazole is taken at multiple doses of 400 mg per day or higher, due to the risk of serious cardiac dysrhythmias and Torsades de Pointes.

Combinations Requiring Caution and Monitoring

Caution is required with many drugs that have a narrow therapeutic index, as their levels may rise significantly. Examples include Warfarin (increased bleeding risk; requires INR monitoring), Phenytoin, Tacrolimus, Cyclosporine, Sulfonylureas (increased risk of hypoglycemia), and Statins such as Atorvastatin and Simvastatin (increased risk of myopathy/rhabdomyolysis). Dose adjustments and careful patient monitoring are necessary when these agents are combined with Fluconazole.

Molecular Targeting of Fungal Sterol Synthesis

The active substance's mechanism is centered on the selective inhibition of the fungal enzyme lanosterol 14-α-demethylase (CYP51). This enzyme is crucial for synthesizing ergosterol, the key structural component of the fungal cell membrane. The molecule directly engages the ergosterol biosynthesis pathway to prevent the conversion that forms this essential sterol.

---

️ Cascade of Membrane Structural Failure

The successful inhibition of the target enzyme initiates a destructive cascade: it causes a deficiency of ergosterol and a simultaneous, toxic accumulation of abnormal precursor molecules, known as 14-α-methyl sterols. The incorporation of these faulty sterols into the developing membrane profoundly disrupts its integrity and increases its permeability, which leads to the eventual fungistatic effect—resulting in the inhibition of fungal cell proliferation.

---

️ Basis for Fungal Selectivity

The physiological effect relies on the drug's high selectivity, meaning it primarily binds to and affects the fungal CYP51 enzyme while demonstrating a much lower affinity for the similar P450 enzymes found in human cells. This mechanistic difference demonstrates a differential affinity, resulting in targeted disruption of fungal cellular processes.

How to Use Дифлазон (Fluconazole) — Official Administration Guidelines

Дифлазон (Fluconazole) must be used strictly according to the specific instructions detailed in official prescribing information, which define the correct route, dosage, frequency, and duration of therapy.

Approved Routes and Forms

Fluconazole is available for two primary modes of administration, ensuring flexibility in treatment:

• Oral Administration: Provided as capsules in strengths such as 50 mg, 100 mg, 150 mg, and 200 mg. An oral suspension is also available. Oral forms may be taken with or without food.
• Intravenous (IV) Infusion: Supplied as a sterile 2 mg/mL solution for infusion. This route is used when oral intake is not feasible.

---

Standard Dosing and Administration Protocol

Administration typically begins with a higher initial amount to rapidly achieve effective drug levels, followed by a sustained daily dose.

Usage Parameter	Regulatory Instruction
Dose Initiation	A loading dose equal to twice the maintenance dose is often given on the first day (Day 1).
Maintenance Dose	Usually 50 mg to 400 mg taken once daily. Doses up to 800 mg/day may be used for severe infections.
Frequency	Primarily once daily. The treatment course duration can range from a single oral dose (150 mg for uncomplicated vaginal candidiasis) to long-term therapy for conditions like cryptococcal meningitis.
IV Infusion Rate	The intravenous solution must be administered slowly, at a rate not exceeding 10 mL/minute.

---

Special Population Adjustments

Official labeling requires specific dose adjustments for certain patient groups:

• Renal Impairment: For patients on multiple-dose regimens with creatinine clearance (CrCl) leq 50 mL/min, the dosage must generally be reduced by 50%.
• Pediatrics: Dosing is calculated based on body weight (mg/kg), and the dosing interval is extended for very young infants (neonates).

Research Evidence / Overview of studies for Дифлазон

Research Evidence for Systemic and Central Nervous System Fungal Diseases

This section will summarize the major clinical studies, including randomized trials and observational cohorts, that evaluated the medicine's role in treating severe, widespread fungal infections and those affecting the brain and spinal cord.

Studies in Systemic Bloodstream Infections (Candidemia)

Research was studied for its role in systemic fungal diseases, such as candidemia (a bloodstream infection), through multicenter retrospective and large observational studies. The research primarily examined outcomes related to 30-day mortality, the risk of recurrence over a year, and the link between antifungal resistance levels in the fungus and patient outcomes. Findings describe patterns observed in the studies, noting that data show patterns related to the specific type of Candida species causing the infection. Comparative evidence is lacking against other types of antifungal treatments in critically ill patient populations. The full impact of increasing non-albicans species prevalence on outcomes related to systemic or functional imbalance is still emerging.

Research for Specific CNS Infections (e.g., Cryptococcal Meningitis)

The medicine was studied for its role as a component of treatment for specific infections of the central nervous system (CNS), such as Cryptococcal meningitis, especially in persons with HIV. Studies used prospective randomized trials and comparative trials, monitoring outcomes like patient survival, neurological stability, and outcomes related to microbiological clearance (CSF culture results). Studies monitored outcomes consistent with its use in the consolidation and long-term maintenance phases. However, research examined whether using the medicine alone for the initial, most acute phase was associated with a slower rate of fungal clearance as opposed to combination regimens. Subgroup findings are uncertain for certain initial treatment approaches, as studies also reported that resistance can emerge when the medicine was observed in trials as a single initial agent.

Evidence for Prevention (Prophylaxis) in Immunocompromised Patients

This section will focus on the research, primarily controlled clinical trials, that investigated the medicine's use to prevent fungal infections from developing in patients undergoing procedures like bone marrow transplantation or intensive chemotherapy.

The medicine was evaluated in numerous short-term Randomized Controlled Trials (RCTs) and comprehensive meta-analyses. These trials focused on populations at high risk for fungal infection. Studies exploring short-term symptom changes reported how the incidence of both systemic and superficial fungal infections evolved in the observed populations compared to control groups receiving a placebo. However, data show patterns related to patient mortality that were mixed when looking at studies involving neutropenic patients who did not undergo transplantation.

Clinical Studies for Localized Mucosal Fungal Infections

This section will detail the types of studies, including trials for recurrence prevention, that have examined the medicine's use for common localized conditions like oral or vaginal candidiasis.

Research examined conditions characterized by fluctuating or episodic manifestations, such as oropharyngeal and vaginal candidiasis. Findings describe patterns observed in the studies related to symptom resolution and outcomes describing episodic or acute changes among the observed populations. Trials for recurrent infections reported how symptoms evolved in the observed populations, documenting periods free from recurrence when evaluated against control groups. Longitudinal tracking in some high-risk patient subgroups describes changes in local fungal colonization patterns and the subsequent isolation of organisms with reduced susceptibility over time.

Common questions about Дифлазон (FAQ)

---

Q: What is Дифлазон used for?

Дифлазон (Fluconazole) is an antifungal medication primarily indicated for the treatment of certain fungal and yeast infections. Its authorized uses typically cover infections of the vagina, mouth, throat, esophagus, abdomen, lungs, and blood. It may also be used in some contexts to help prevent fungal infection in certain patients with compromised immune systems.

---

Q: Is Дифлазон the same as Fluconazole?

Yes, Дифлазон is a brand name for the active pharmaceutical ingredient Fluconazole. Fluconazole is the generic name for this particular azole antifungal agent. The brand and generic versions contain the same active compound.

---

Q: What are the potential side effects of Дифлазон?

Like many medications, Дифлазон may be associated with side effects. Commonly reported effects often include headache, dizziness, and gastrointestinal discomfort such as nausea, vomiting, or abdominal pain. Less commonly, potential skin reactions or changes in liver enzyme levels may occur. Patients are advised to consult a healthcare provider for a complete list of possible adverse effects.

---

Q: How long does Дифлазон typically take to work?

The time required for Дифлазон to show an effect can vary significantly based on the specific type, location, and severity of the fungal infection being treated. For some mild infections, patients may report symptomatic improvement within a few days. For more extensive or systemic infections, a longer course of treatment is usually required, and the effect may take longer to observe. A healthcare professional can provide information specific to the prescribed regimen.

---

Q: Can Дифлазон be taken with other medications?

Дифлазон has the potential to interact with a wide range of other medications, including certain blood thinners (anticoagulants), statins, some antibiotics, and specific heart medications. These interactions can potentially alter the effectiveness or safety profile of one or both drugs. It is essential to inform the prescribing healthcare provider of all current medications, supplements, and herbal products being used prior to starting treatment with Дифлазон.

---

Q: Can Дифлазон cause liver problems?

In rare instances, the use of Fluconazole, the active ingredient in Дифлазон, has been associated with serious liver injury. Periodic monitoring of liver function tests may be recommended by a healthcare provider during certain treatment courses, particularly those that are prolonged. Patients should contact a healthcare professional immediately if they experience symptoms such as persistent nausea, yellowing of the skin or eyes (jaundice), or dark urine.

---

Q: Is Дифлазон safe for children?

Fluconazole, the drug's active ingredient, has been studied for use in children and is available in formulations suitable for pediatric use. The appropriateness of using Дифлазон in children is determined by a pediatric healthcare provider based on the specific infection, the child's weight, and other individual health factors. Its use should be carefully monitored.

---

Q: What should I do if I miss a dose of Дифлазон?

Specific actions for a missed dose depend on the individual's prescribed dosing schedule and the infection being treated. General guidelines suggest taking the missed dose as soon as it is remembered, unless it is almost time for the next scheduled dose. Patients should contact their pharmacist or prescribing healthcare provider for instruction tailored to their specific treatment plan.

Storage and Disposal of Diflazon (Fluconazole)

The official storage conditions for Fluconazole are mandatory for maintaining product stability and vary by formulation. Fluconazole capsules must be stored below 30 C (86 F).

The solution for infusion requires a narrower temperature range, generally between 20 C and 25 C (68 F and 77 F), and must be strictly protected from freezing and excessive heat.

General Storage Rules

Requirement	Rule
Container	Keep the medicine in its original container and keep it tightly closed
Child Safety	Keep out of the sight and reach of children

Disposal

Expired or unused Fluconazole must be disposed of according to local and national regulations. To protect the environment, the medicine must not be thrown away via household trash or wastewater.